AVALON GLOBOC.NEW -,0001
AVALON GLOBOC.NEW -,0001
Aktie · US05344R2031 · ALBT · A3D4QG (XNCM)
Übersicht Finanzkennzahlen
2,79 EUR
-6,45 % -0,19 EUR
Frankfurt (XNAS) · Aktuelle Kurse und Charts bei MoneyPeak
10.06.2025 19:59

Aktuelle Kurse von AVALON GLOBOC.NEW -,0001

BörseTickerWährungLetzter UmsatzKursTagesveränderung
XNAS: NASDAQ
NASDAQ
ALBT
USD
10.06.2025 19:59
3,19 USD
3,26 USD
-2,15 %

Performance

Heute Woche Monat 3 Monate 6 Monate 1 Jahr 5 Jahre
-6,63 % -8,87 % -19,38 % -55,76 % -27,95 % -57,36 % -98,80 %

Firmenprofil zu AVALON GLOBOC.NEW -,0001 Aktie

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.

Unternehmensdaten

Name AVALON GLOBOC.NEW -,0001
Firma Avalon GloboCare Corp.
Symbol ALBT
Website https://www.avalon-globocare.com
Heimatbörse XNCM Frankfurt
WKN A3D4QG
ISIN US05344R2031
Wertpapierart Aktie
Sektor Real Estate
Branche Real Estate - Services
CEO Dr. David K. Jin M.D., Ph.D.
Land Vereinigte Staaten von Amerika
Währung EUR
Mitarbeiter 0,0 T
Adresse 4400 Route 9 South, 07728 Freehold
IPO Datum 2018-03-27

Aktien-Splits

Datum Split
28.10.2024 1:15

Kennungs-Wechsel

Datum Von Zu
10.11.2022 AVCO ALBT

Ticker Symbole

Name Symbol
NASDAQ ALBT

Weitere Aktien

Investoren die AVALON GLOBOC.NEW -,0001 die halten, haben auch folgende Aktien im Depot:
LB.HESS.THR.CARRARA07H/21
LB.HESS.THR.CARRARA07H/21 Anleihe
MORGAN STANLEY B.V. EQ LKD NTS 28/02/28
MORGAN STANLEY B.V. EQ LKD NTS 28/02/28 Anleihe
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios. Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Impressum Datenschutz Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025